The next intake of the EUPATI Patient Expert Training is now open for registrations!
The EUPATI Patient Expert Training Programme is a training programme about the medicines’ development process. It covers the entire lifecycle of medicines research and development (R&D), from the design and execution of clinical trials to regulatory processes and Health Technology Assessment (HTA).
In addition to detailed information on each step of the process, the training also describes how patients can be involved at each stage. The overall objective of the programme is to obtain a thorough understanding of the medicines R&D process, the patients’ role within and build capacity among the patient community to take on an active role in collaboration with the other involved stakeholders.
Graduates of the EUPATI Patient Expert Programme (EUPATI Fellow Programme) are also known as EUPATI Fellows. The EUPATI Fellow title certifies the knowledge gained and gives graduates the opportunity to be recognised as expert patients.
While the programme is mainly addressed to patients and patient representatives (e.g., carers and persons working for patient organisations), it is open to all individuals interested in medicines R&D and patient engagement. The programme does not focus on any specific disease area, examples and case studies are provided from a variety of different disease areas. The only requirement for enrolment is a good proficiency of English, as the training is provided in English.
- Find out all information about the training on the EUPATI Open Classroom
- Download and save the training brochure
- Fill out the registration form before 01 November 2022
Any questions? Please contact firstname.lastname@example.org.
We have successfully launched a new program called Educational Radio Program for NMD Community 2021. Find more on host countries, show dates, and much more:
We are pleased to announce the partnership between EAMDA and ECMTF (European Charcot Marie Tooth Federation), established through a signed Memorandum of Cooperation, for the benefit of the NMD community across Europe.
The European CMT Federation is a voluntary non-profit federation registered in Belgium, formed by national organizations supporting people living with Charcot Marie Tooth disease, a neuromuscular condition that affects 1 in 2500 people worldwide. ECMTF was founded in 2016 and has rapidly grown since then, extending its collaboration beyond the European border, towards USA, China or Israel.
Not only that EAMDA and ECMTF share common interests and goals, but we do consider that this cooperation will generate a lot of benefits for the people we represent, through the sharing of expertise and through common projects that will lead to a significant increase in the quality of life of people with neuromuscular disorders, CMT included.
This EAMDA-ECMTF partnership will also help us become a stronger and more influential voice for the NMD community, that will not only increase public awareness of these diseases, but also help us create a wider stakeholder involvement network.
“Together we are stronger” as our partners from The European Charcot Marie Tooth Federation (ECMTF) say!
The ProDGNE consortium is pleased to invite you to the ProDGNE Kick-Off Webinar. In this webinar we will present ProDGNE, a 3 year transnational pre-clinical research project which brings together patients and researchers from Europe and Canada to develop an innovative therapeutic compound to treat GNE Myopathy (GNEM), a rare genetic muscle disease affecting young adults. Speakers: – Fabrizio Pertusati, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, UK – Hanns Lochmüller, University of Ottawa Faculty of Medicine and The Ottawa Hospital Department of Medicine, Canada – Michela Onali, Gli Equilibristi HIBM, Italy – Paula Videira, Faculdade de Ciências e Tecnologia at Universidade NOVA de Lisboa, Portugal – Pierluigi Caboni, Department of Life and Environmental Sciences, University of Cagliari, Italy – Rüdiger Horstkörte, Medical Faculty, Martin-Luther University Halle-Wittenberg, Germany ProDGNE is funded in the framework of the European Joint Programme on Rare
Please follow this link to register. https://us02web.zoom.us/webinar/register/9616216054703/WN_AzgzW3uLSHmD-Tfe5mIxLA
SMA NBS Alliance published a whitepaper and call of action on the need for newborn screening for Spinal Muscular Atrophy (SMA). More information you can find on https://www.sma-screening-alliance.org/
EAMDA has 2 new advocacy experts in medicines research, development and therapeutic innovation!
Jana Popova, EC Member of EAMDA and member of the Bulgarian Association for Neuromuscular Diseases and Arabela Acalinei, secretary of EAMDA and President of Neuro Move CMT Association in Romania are both graduates of the European Patients’ Academy on Therapeutic Innovation (EUPATI).
EUPATI is a 15 months intensive training course that has been specifically designed to meet the needs of patients and patient advocates who have the motivation and skill set to acquire and apply expert-level knowledge across the whole spectrum of the medicine research and development process. It coveres topics like medicine research and development, clinical trials, regulatory affairs, pharmacovigilance, HTA and therapeutic innovation.
As an organization that strongly believes in a good representation of our members, we are glad that EAMDA’s team members are capable of engaging European stakeholders, aligned to EU policies, good practices and inovations.
There is an updated version of ‘Duchenne and you’ website available for you to visit at https://duchenneandyou.eu/
Welcome to visit the site and get useful information on DMD (articles & videos included).
IBAN: SI56 0201 1026 2111 086
VAT No.: 64611400
Bank name & address:
Nova Ljubljanska banka d.d.
Trg republike 2